News
Featured
24 June 2026
RQ Bio Announces $115 Million (£85.5 Million) Series A Financing to Advance Long-Acting Antibody Programme RQB01 for Full Season Influenza Prevention
Professor Paul Kellam Elected Fellow of the Academy of Medical Sciences
21 May 2026
Welcoming new talent: Strengthening our mission through research and innovation
4 August 2025
Advancing global health: Our team at the BIO international convention 2025
12 June 2025
RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals
9 January 2025
RQ Biotechnology Ltd. Celebrates Milestone with Grant of GB Patent Covering its Licensed Clinical-Stage Antibody for the Prevention and Treatment of COVID-19
18 March 2024
